December 2024 Supplement Peripheral Arterial Clot? #POUNCEIT When minutes matter – remove acute or chronic thrombi or emboli without aspiration, thrombolytics, or capital equipment. Sponsored by Surmodics, Inc.

Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

Thoracic aortic aneurysm (TAA) is a potentially life-threatening disorder that without intervention carries a poor prognosis. Once diagnosed, the 3-year survival for large degenerative TAAs (> 60 mm in diameter) is approximately 20%. 1 Hospital admissions in the United Kingdom for TAAs have doubled in the last decade, and von Allmen and colleagues reported a TAA hospital admission rate of nine ...

November 4, 2024—The first clinical use of the Javelin peripheral intravascular lithotripsy (IVL) catheter (Shockwave Medical) for the treatment of peripheral artery disease (PAD) was evaluated in pooled data from the premarket, prospective, single-arm Mini S feasibility study and the FORWARD PAD investigational device exemption (IDE) study. The Javelin device features a forward-shifted IVL ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid based on a radiopaque biocompatible copolymer. According to iVascular, OPAL is a prospective, single-arm, multicenter study that will enroll 70 patients requiring peripheral embolization. It will be conducted in collaboration with 10 Spanish centers specialized in ...

News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

November 26, 2024—Bentley InnoMed GmbH announced the first-in-human implantation of the BeFlared stent graft system, which recently received CE Mark certification as a dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR). The company noted that the first-in-human FEVAR procedure was performed by Professor Stéphan Haulon, MD, a vascular surgeon at the Hôpital Marie ...